Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 6Hypoxia 4Sarcoma 3Prostatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Melanoma 2Solid Tumors 1Solid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × TH 302 × Clear all
NCT00495144 2012-07-27

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1 Completed
129 enrolled

Hypoxia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡